ArticleFrontiers in oncology2024

A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancer.

Song Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.